Rev3l-KO Mouse
一般名
Rev3l-KO
製品ID
S-KO-17672
背景情報
C57BL/6JCya
系統ID
KOCMP-19714-Rev3l-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Rev3l-KO Mouse（カタログ番号S-KO-17672）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Rev3l-KO
系統ID
KOCMP-19714-Rev3l-B6J-VA
遺伝子名
製品ID
S-KO-17672
遺伝子別名
Rev, Rev3, Sez4
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 10
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000019986
NCBIトランスクリプトID
NM_011264
ターゲット領域
Exon 2
有効領域の大きさ
~1.3 kb
遺伝子研究の概要
REV3L, encoding the catalytic subunit of DNA polymerase ζ (Pol ζ), is crucial for error-prone translesion synthesis (TLS), a DNA damage tolerance mechanism. TLS helps cells bypass DNA lesions, protecting them from potentially harmful DNA damage, yet it also poses a risk to genome stability due to its error-prone nature [3,4,5,6,7,9].
Multiple studies have shown the significance of REV3L in cancer. In the population of Jammu and Kashmir, three REV3L single-nucleotide variants (rs1002481, rs462779, and rs465646) were significantly associated with an increased risk of non-small cell lung cancer (NSCLC) under the recessive model [1]. In NSCLC H1299 cells, cisplatin induced REV3L expression, and overexpression of REV3L conferred cisplatin resistance, while knockdown sensitized the cells to cisplatin treatment, suggesting REV3L as a potential target for NSCLC chemotherapy [2]. Similar roles were found in esophageal squamous cell carcinoma, gliomas, and cervical cancer, where REV3L was upregulated, associated with tumor progression and chemoresistance [3,5,6]. In myelodysplastic syndrome, a REV3L mutation (c.9253-6T>C) was associated with poor prognosis [8]. Also, in non-small-cell lung cancer, circular RNA PRMT5 promoted cisplatin-resistance via the miR-4458/REV3L axis [10].
In conclusion, REV3L plays a key role in DNA damage tolerance through TLS. Its dysregulation is associated with various cancers, contributing to tumor progression and chemoresistance. Understanding the function of REV3L through these studies provides potential diagnostic and therapeutic targets for multiple cancer types.
References：
1. Jamwal, Rajeshwer Singh, Mahajan, Nikita, Bhat, Gh Rasool, Kumar, Rakesh, Bhat, Audesh. 2021. REV3L single nucleotide variants lead to increased susceptibility towards non-small cell lung cancer in the population of Jammu and Kashmir. In Cancer epidemiology, 75, 102047. doi:10.1016/j.canep.2021.102047. https://pubmed.ncbi.nlm.nih.gov/34655923/
2. Wang, Wenjie, Sheng, Wenjiong, Yu, Chenxiao, Zhang, Huojun, Zhang, Shuyu. 2015. REV3L modulates cisplatin sensitivity of non-small cell lung cancer H1299 cells. In Oncology reports, 34, 1460-8. doi:10.3892/or.2015.4121. https://pubmed.ncbi.nlm.nih.gov/26165320/
3. Zhu, Xiaozhong, Zou, Shitao, Zhou, Jundong, Wu, Jinchang, Chen, Yihong. 2016. REV3L, the catalytic subunit of DNA polymerase ζ, is involved in the progression and chemoresistance of esophageal squamous cell carcinoma. In Oncology reports, 35, 1664-70. doi:10.3892/or.2016.4549. https://pubmed.ncbi.nlm.nih.gov/26752104/
4. Tirman, Stephanie, Quinet, Annabel, Wood, Matthew, Zou, Lee, Vindigni, Alessandro. . Temporally distinct post-replicative repair mechanisms fill PRIMPOL-dependent ssDNA gaps in human cells. In Molecular cell, 81, 4026-4040.e8. doi:10.1016/j.molcel.2021.09.013. https://pubmed.ncbi.nlm.nih.gov/34624216/
5. Wang, Huibo, Zhang, Shu-Yu, Wang, Shuai, Lu, Daru, Zhao, Shiguang. . REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy. In Neuro-oncology, 11, 790-802. doi:10.1215/15228517-2009-015. https://pubmed.ncbi.nlm.nih.gov/19289490/
6. Yang, Li, Shi, Tingyan, Liu, Fei, Yang, Gong, Cheng, Xi. 2015. REV3L, a promising target in regulating the chemosensitivity of cervical cancer cells. In PloS one, 10, e0120334. doi:10.1371/journal.pone.0120334. https://pubmed.ncbi.nlm.nih.gov/25781640/
7. Halas, Agnieszka, Fijak-Moskal, Jolanta, Kuberska, Renata, Sledziewska-Gojska, Ewa, Płoski, Rafał. 2021. Developmental delay with hypotrophy associated with homozygous functionally relevant REV3L variant. In Journal of molecular medicine (Berlin, Germany), 99, 415-423. doi:10.1007/s00109-020-02033-3. https://pubmed.ncbi.nlm.nih.gov/33474647/
8. Oliveira, Roberta Taiane G de, França, Ivo Gabriel F, Junior, Howard L R, Magalhães, Silvia M M, Pinheiro, Ronald F. 2020. c.9253-6T>c REV3L: A novel marker of poor prognosis in Myelodysplastic syndrome. In Hematology, transfusion and cell therapy, 43, 377-381. doi:10.1016/j.htct.2020.05.006. https://pubmed.ncbi.nlm.nih.gov/32682781/
9. Wang, Fengting, Li, Pan, Shao, Yuan, Xiao, Wei, Li, Xialu. . Site-specific proteolytic cleavage prevents ubiquitination and degradation of human REV3L, the catalytic subunit of DNA polymerase ζ. In Nucleic acids research, 48, 3619-3637. doi:10.1093/nar/gkaa096. https://pubmed.ncbi.nlm.nih.gov/32064513/
10. Pang, Jun, Ye, Liwen, Zhao, Dan, Zhao, Ding, Chen, Qingwei. 2020. Circular RNA PRMT5 confers cisplatin-resistance via miR-4458/REV3L axis in non-small-cell lung cancer. In Cell biology international, 44, 2416-2426. doi:10.1002/cbin.11449. https://pubmed.ncbi.nlm.nih.gov/32808744/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。